Global Beyond the Pill Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Beyond the Pill Market Research Report 2024
Beyond the pill refers to a shift in the pharmaceutical industry towards providing holistic healthcare services and products that go beyond traditional drug-based treatments. The term "beyond the pill" emphasizes the need for pharmaceutical companies to provide additional support and services to patients beyond simply prescribing medications.Beyond the pill offerings can include a wide range of products and services, such as patient education programs, digital health technologies, medical devices, and patient monitoring services. The goal of these offerings is to improve patient outcomes and satisfaction while also providing additional revenue streams for pharmaceutical companies.
According to MRAResearch’s new survey, global Beyond the Pill market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Beyond the Pill market research.
The beyond the pill market has seen significant growth in recent years, driven by factors such as the increasing importance of patient-centered care, the rise of digital health technologies, and the growing demand for value-based healthcare. Key players in the beyond the pill market include major pharmaceutical companies such as Pfizer, Roche, Novartis, and Sanofi, as well as a number of smaller startups and technology companies.
The beyond the pill market is expected to continue to grow as more pharmaceutical companies recognize the importance of providing holistic healthcare solutions and as patients continue to demand more personalized and integrated care.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Beyond the Pill market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novartis AG
Sanofi S.A
Novo Nordisk A/S
Eli Lilly and Company
F. Hoffmann-La Roche AG (Flatiron Health)
Otsuka Pharmaceuticals Co., Ltd
Amgen, Inc.
AstraZeneca Plc
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
Segment by Type
Services
Monitoring
Assistance
Diabetes
Oncology
Cardiovascular Diseases
Asthma
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Beyond the Pill report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Beyond the Pill market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Beyond the Pill market research.
The beyond the pill market has seen significant growth in recent years, driven by factors such as the increasing importance of patient-centered care, the rise of digital health technologies, and the growing demand for value-based healthcare. Key players in the beyond the pill market include major pharmaceutical companies such as Pfizer, Roche, Novartis, and Sanofi, as well as a number of smaller startups and technology companies.
The beyond the pill market is expected to continue to grow as more pharmaceutical companies recognize the importance of providing holistic healthcare solutions and as patients continue to demand more personalized and integrated care.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Beyond the Pill market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis AG
Sanofi S.A
Novo Nordisk A/S
Eli Lilly and Company
F. Hoffmann-La Roche AG (Flatiron Health)
Otsuka Pharmaceuticals Co., Ltd
Amgen, Inc.
AstraZeneca Plc
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
Segment by Type
Services
Monitoring
Assistance
Segment by Application
Diabetes
Oncology
Cardiovascular Diseases
Asthma
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Beyond the Pill report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source